<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741273</url>
  </required_header>
  <id_info>
    <org_study_id>ZP-005</org_study_id>
    <nct_id>NCT00741273</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults</brief_title>
  <official_title>An Open-label, Two-stage, Dose-escalation, Parallel Group Study to Evaluate the Safety and Pharmacokinetics Profile of Proellex® (CDB-4124) in Female Patients With Impaired Hepatic Function and Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and pharmacokinetics of two doses of orally administered
      Proellex® in female patients with impaired hepatic function and healthy volunteers with
      normal hepatic function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      16 subjects will be allocated to 2 groups. The test group will consist of 8 female patients
      with moderately impaired hepatic function meeting the Child-Pugh Class B severity criteria,
      while the control group will consist of 8 healthy female adult volunteers. During Stage I,
      all subjects will receive a single oral dose of 25mg of Proellex® (fasting state) and be
      followed in a Clinical Research Unit (CRU) for about three days. Only subjects who do not
      experience serious adverse events (SAEs) or adverse events (AEs) that are determined by
      Investigator to be possibly, probably or definitely related to the treatment will participate
      in Stage II. The dose will be increased to a single dose of 50mg of Proellex® (fasting state)
      and subjects will be followed in a Clinical Research Unit (CRU) for about three days.
      Subjects will undergo blood draws at several time points.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Blood Concentration (Cmax)</measure>
    <time_frame>48 hours</time_frame>
    <description>Cmax of a single dose of 25mg and 50mg of Proellex® in female patients with impaired hepatic function and in volunteers with normal hepatic function, assessed from samples collected at: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 5, 7, 9, 12, 16, 20, 24, 32, 36, 40 and 48 hours post dose..</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proellex Half-life (T1/2)</measure>
    <time_frame>48 hours</time_frame>
    <description>Time for Proellex concentration to decrease by half (T1/2) of a single dose of 25mg and 50mg of Proellex® in female patients with impaired hepatic function and in volunteers with normal hepatic function,measured from samples collected at: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 5, 7, 9, 12, 16, 20, 24, 32, 36, 40 and 48 hours post dose..</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC0-t) for Proellex</measure>
    <time_frame>48 hours</time_frame>
    <description>AUC0-t of a single dose of 25mg and 50mg of Proellex® in female patients with impaired hepatic function and in volunteers with normal hepatic function, measured from samples collected at: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 5, 7, 9, 12, 16, 20, 24, 32, 36, 40 and 48 hours post dose.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Impaired Liver Function</condition>
  <arm_group>
    <arm_group_label>Proellex 25 mg healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proellex 25 mg in healthy females</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proellex 25 mg Impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proellex 50 mg in hepatically impaired females</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex</intervention_name>
    <description>Proellex 25 mg capsule, single dose</description>
    <arm_group_label>Proellex 25 mg healthy</arm_group_label>
    <arm_group_label>Proellex 25 mg Impaired</arm_group_label>
    <other_name>Telapristone acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Speak, read, and understand English or Spanish and is willing and able to provide
             written informed consent on an IRB-approved form prior to the initiation of any study
             procedures;

          -  Female, between the ages of 18 and 48 years with Body Mass Index (BMI) between 18 and
             39, inclusive, are preferred; however, subjects up to 62 years old, inclusive, may
             participate;

          -  Subjects with moderate hepatic insufficiency must meet the Class B level of the
             Child-Pugh criteria;

          -  Subjects must have evidence of stable hepatic impairment;

          -  If on medications for treatment of the complications of liver disease, and other
             concomitant chronic illnesses, subjects must have been taking the medications at a
             stable dose for at least 10 days prior to the first dosing date and are then to be
             continued at the same dose for the duration of the study;

          -  Non-smokers are preferred, but light to moderate smoking will be allowed (no more than
             10 cigarettes/day)

          -  Subject is willing to remain in the clinic for the screening visit and for two
             treatment visits (approximately 3 days for each treatment visit);

          -  Other inclusion criteria may apply

        Exclusion Criteria:

          -  Past or present history of an allergic reaction to the formulations administered in
             this study, or in the opinion of the Investigator, suggesting an increased potential
             for an adverse hypersensitivity;

          -  Pregnant or lactating females, or women who are attempting or expecting to become
             pregnant at any time during the study or one month after the study;

          -  A physical illness within three (3) months of the study that would interfere with the
             study as determined by the Investigator;

          -  An acute illness within five (5) days of study medication administration;

          -  Positive urine drug screen at the screening visit based on laboratory testing;

          -  Other exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre van As, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Repros Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014-3616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <results_first_submitted>June 27, 2014</results_first_submitted>
  <results_first_submitted_qc>August 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2014</results_first_posted>
  <last_update_submitted>August 8, 2014</last_update_submitted>
  <last_update_submitted_qc>August 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy</title>
          <description>Proellex single dose each of 25 mg and 50 mg in healthy females</description>
        </group>
        <group group_id="P2">
          <title>Impaired</title>
          <description>Proellex single dose each of 25 mg and 50 mg in hepatically impaired females</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT and Safety populations were the same</population>
      <group_list>
        <group group_id="B1">
          <title>Healthy</title>
          <description>Healthy females</description>
        </group>
        <group group_id="B2">
          <title>Mpaired</title>
          <description>Hepatically impaired females</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.4" spread="4.1"/>
                    <measurement group_id="B2" value="54.1" spread="4.8"/>
                    <measurement group_id="B3" value="47.8" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Blood Concentration (Cmax)</title>
        <description>Cmax of a single dose of 25mg and 50mg of Proellex® in female patients with impaired hepatic function and in volunteers with normal hepatic function, assessed from samples collected at: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 5, 7, 9, 12, 16, 20, 24, 32, 36, 40 and 48 hours post dose..</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proellex 25 mg Healthy</title>
            <description>Proellex 25 mg in healthy females
Proellex: Proellex 25 mg capsule, single dose</description>
          </group>
          <group group_id="O2">
            <title>Proellex 25 mg Impaired</title>
            <description>Proellex 50 mg in hepatically impaired females
Proellex: Proellex 25 mg capsule, single dose</description>
          </group>
          <group group_id="O3">
            <title>Proellex 50 mg Healthy</title>
            <description>Proellex 50 mg in healthy females
Proellex: Proellex 50 mg capsule, single dose</description>
          </group>
          <group group_id="O4">
            <title>Proellex 50 mg Impaired</title>
            <description>Proellex 50 mg in impaired females
Proellex: Proellex 50 mg capsule, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Blood Concentration (Cmax)</title>
          <description>Cmax of a single dose of 25mg and 50mg of Proellex® in female patients with impaired hepatic function and in volunteers with normal hepatic function, assessed from samples collected at: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 5, 7, 9, 12, 16, 20, 24, 32, 36, 40 and 48 hours post dose..</description>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="827.5" spread="312.9"/>
                    <measurement group_id="O2" value="587.6" spread="261.3"/>
                    <measurement group_id="O3" value="1589.5" spread="482.3"/>
                    <measurement group_id="O4" value="974.0" spread="400.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC0-t) for Proellex</title>
        <description>AUC0-t of a single dose of 25mg and 50mg of Proellex® in female patients with impaired hepatic function and in volunteers with normal hepatic function, measured from samples collected at: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 5, 7, 9, 12, 16, 20, 24, 32, 36, 40 and 48 hours post dose.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proellex 25 mg Healthy</title>
            <description>Proellex 25 mg in healthy females
Proellex: Proellex 25 mg capsule, single dose</description>
          </group>
          <group group_id="O2">
            <title>Proellex 25 mg Impaired</title>
            <description>Proellex 25 mg in hepatically impaired females
Proellex: Proellex 25 mg capsule, single dose</description>
          </group>
          <group group_id="O3">
            <title>Proellex 50 mg Healthy</title>
            <description>Proellex 50 mg in healthy females
Proellex: Proellex 50 mg capsule, single dose</description>
          </group>
          <group group_id="O4">
            <title>50 mg Impaired</title>
            <description>Proellex 50 mg in impaired females
Proellex: Proellex 50 mg capsule, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC0-t) for Proellex</title>
          <description>AUC0-t of a single dose of 25mg and 50mg of Proellex® in female patients with impaired hepatic function and in volunteers with normal hepatic function, measured from samples collected at: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 5, 7, 9, 12, 16, 20, 24, 32, 36, 40 and 48 hours post dose.</description>
          <units>ng x min/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5147.2" spread="2647.3"/>
                    <measurement group_id="O2" value="3603.1" spread="1777.2"/>
                    <measurement group_id="O3" value="9062.4" spread="4616.1"/>
                    <measurement group_id="O4" value="6988.6" spread="3289.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proellex Half-life (T1/2)</title>
        <description>Time for Proellex concentration to decrease by half (T1/2) of a single dose of 25mg and 50mg of Proellex® in female patients with impaired hepatic function and in volunteers with normal hepatic function,measured from samples collected at: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 5, 7, 9, 12, 16, 20, 24, 32, 36, 40 and 48 hours post dose..</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proellex 25 mg Healthy</title>
            <description>Proellex 25 mg in healthy females
Proellex: Proellex 25 mg capsule, single dose</description>
          </group>
          <group group_id="O2">
            <title>Proellex 25 mg Impaired</title>
            <description>Proellex 25 mg in hepatically impaired females
Proellex: Proellex 25 mg capsule, single dose</description>
          </group>
          <group group_id="O3">
            <title>Proellex 50 mg Healthy</title>
            <description>Proellex 50 mg in healthy females
Proellex: Proellex 50 mg capsule, single dose</description>
          </group>
          <group group_id="O4">
            <title>50 mg Impaired</title>
            <description>Proellex 50 mg in impaired females
Proellex: Proellex 50 mg capsule, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Proellex Half-life (T1/2)</title>
          <description>Time for Proellex concentration to decrease by half (T1/2) of a single dose of 25mg and 50mg of Proellex® in female patients with impaired hepatic function and in volunteers with normal hepatic function,measured from samples collected at: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 5, 7, 9, 12, 16, 20, 24, 32, 36, 40 and 48 hours post dose..</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="8.4"/>
                    <measurement group_id="O2" value="37.9" spread="18.9"/>
                    <measurement group_id="O3" value="24.2" spread="10.1"/>
                    <measurement group_id="O4" value="30.9" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events are reported together in each group for exposure to both 25mg Proellex and 50 mg Proellex</desc>
      <group_list>
        <group group_id="E1">
          <title>Proellex Healthy</title>
          <description>Proellex 25 mg and 50 mg in healthy females
Proellex: Proellex 25 mg and 50 mg capsule, single dose each</description>
        </group>
        <group group_id="E2">
          <title>Proellex Impaired</title>
          <description>Proellex 25 mg and 50 mg in hepatically impaired females
Proellex: Proellex 25 mg and 50 mg capsule, single dose each</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor’s Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor’s Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Wike</name_or_title>
      <organization>Repros Therapeutics</organization>
      <phone>2817193402</phone>
      <email>jwike@reprosrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

